复星医药发布重大对外投资暨关联交易公告：B轮融资及股权转让详情解析
一、交易概述与核心要点
上海复星医药（集团）股份有限公司（以下简称“复星医药”）于2026年5月26日发布公告，披露其控股子公司复星医药产业将参与苏州星曜坤泽生物医药股份有限公司（以下简称“星曜坤泽”）的B轮融资及股权转让。本次交易金额高达人民币41437.50万元，预计复星医药产业将持有星曜坤泽20.8709%的股权。
- 交易结构：复星医药产业将出资21781.3912万元认缴星曜坤泽新增注册资本293.6752万元（即增资），同时出资19656.1088万元受让苏州基金、天津基金持有的星曜坤泽存续注册资本308.6511万元（即股权转让）。
- 估值确认：B轮融资对应投前估值为17.47亿元，股权转让估值为15亿元（考虑老股转让折扣率）。
- 参与方：共12方新投资者参与增资，6方参与股权转让，包括复星医药产业、凯泰智生、凯泰宏源、方良昌、许世伟、科法达安、杭州谦和、上海得时、TG Sino-Dragon、华金领致、华金智尚、太浩二期。
- 关联交易：由于复星医药部分董事、高管兼任苏州基金、天津基金投委会成员，构成关联交易，已通过董事会审议，相关董事回避表决，独立非执行董事认可，无需股东大会批准。
二、标的公司星曜坤泽详细信息
- 成立时间：2021年5月，注册地江苏苏州。
- 主营业务：肝病创新药物研发，核心产品包括siRNA创新药HT-101注射液、中和抗体HT-102注射液及HT-101与HT-102联用，均处于临床II期阶段，HT-101及其联用已被国家药监局纳入突破性治疗药物程序。
- 财务状况：截至2024年末总资产2805万元，所有者权益为-549万元，负债3355万元。2024年营业收入21万元，净利润-5835万元。2025年10月末总资产1582万元，所有者权益-108万元，负债1690万元，2025年前10月无收入，净利润-1808万元。
- 研发进展及风险：主要管线处于临床研究阶段，尚无上市产品，药品研发存在进度及上市审批的不确定性，未来销售情况亦存在诸多不确定风险。
三、投资及交易定价分析
- 估值依据：采用市场法，以市研率（EV/研发支出）为核心指标，参照恒瑞医药、舒泰神、华兰生物等上市公司数据，经修正后确定标的公司估值为17.87亿元，B轮融资投前估值17.47亿元，股权转让估值15亿元。
- 增资与转让对价：复星医药产业认缴新增注册资本293.6752万元，增资对价21781.3912万元；受让存续注册资本308.6511万元，转让对价19656.1088万元。
- 交割条件：增资、转让交割各自独立，B轮融资交割为股权转让前提，各投资方最终持股比例以实际交割为准。
- 公司治理：交易完成后，星曜坤泽董事会维持4名董事（苏州基金、天津基金提名3名，安吉科泉提名1名），监事1名，总经理1名。
四、交易影响与风险提示
- 投资目的：本次投资将丰富复星医药在肝病治疗领域的产品管线，增强核心竞争力，若研发顺利推进并获批上市，有望打破慢性乙肝传统治疗瓶颈，实现功能性治愈，具有较大市场潜力，可能显著提升公司估值及市场关注度。
- 风险提示：
- 标的公司产品仍处于临床阶段，研发和上市存在不确定性，投资存在较大风险。
- 未来如产品上市，销售情况受需求、市场竞争、渠道等多重因素影响，存在业绩波动风险。
- 本次交易对价支付及交割须满足多项先决条件，部分投资方交割失败不影响其他方交割。
五、审议程序及历史关联交易
- 审议进程：独立非执行董事事前认可，董事会7名非关联董事一致通过，无需股东大会批准。
- 历史关联交易：过去12个月内，复星医药与苏州基金、天津基金及其控股子公司之间发生日常关联交易合计金额不大，主要包括销售原材料、提供劳务、房屋租赁及物业管理等。
六、对投资者与股价的敏感影响
- 投资者关注重点：
- 复星医药加码肝病创新药领域，若星曜坤泽核心管线突破临床并上市，有望推动公司业绩与估值显著提升。
- 本次交易虽为关联交易，但已充分合规审议，未触及重大资产重组红线。
- 高研发投入与潜在市场空间，投资者应关注未来临床进展及政策变化。
- 风险较高，投资者需警惕药品研发的不确定性及上市后的市场接受度。
七、结论
本次复星医药大额投资星曜坤泽，将对公司肝病创新药布局产生重要影响，若标的公司产品突破临床并上市，极有可能成为股价催化剂。投资者应持续关注后续临床进展及政策动向。
免责声明
本文仅为新闻报道及投资参考，不构成任何投资建议。投资者需结合自身风险承受能力，充分了解交易风险及其不确定性，谨慎决策。
English Version:
Fosun Pharma Announces Major External Investment and Related Transaction: In-depth Analysis of Series B Financing and Equity Transfer
1. Transaction Overview and Key Points
Shanghai Fosun Pharma (Group) Co., Ltd. (“Fosun Pharma”) announced on May 26, 2026, that its subsidiary Fosun Pharma Industrial will participate in Series B financing and equity transfer of Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd. (“Xingyao Kunze”). The transaction value totals RMB 414.375 million, and Fosun Pharma Industrial is expected to hold a 20.8709% stake in Xingyao Kunze.
- Transaction Structure: Fosun Pharma Industrial will invest RMB 217.813912 million to subscribe to new registered capital of RMB 2.936752 million (capital increase), and RMB 196.561088 million to acquire existing registered capital of RMB 3.086511 million from Suzhou Fund and Tianjin Fund (equity transfer).
- Valuation: Series B pre-money valuation is RMB 1.747 billion; equity transfer valuation is RMB 1.5 billion (discount for old shares).
- Participants: 12 new investors in capital increase, 6 in equity transfer, including Fosun Pharma Industrial, Kaitai Zhisheng, Kaitai Hongyuan, Fang Liangchang, Xu Shihui, Kefa Da’an, Hangzhou Qianhe, Shanghai Deshi, TG Sino-Dragon, Huajin Lingzhi, Huajin Zhishang, Taihao Phase II.
- Related Party Transaction: Some directors/executives of Fosun Pharma also serve as investment committee members of Suzhou Fund and Tianjin Fund; the transaction constitutes a related party transaction, approved by the board, with related directors abstaining and independent non-executive directors approving. No shareholder meeting required.
2. Xingyao Kunze Company Details
- Established: May 2021, Suzhou, Jiangsu.
- Main Business: Innovative liver disease drug R&D, main products include siRNA innovative drug HT-101 injection, neutralizing antibody HT-102 injection, and combination of HT-101 & HT-102. All are in Phase II clinical trials and have been included in the National Medical Products Administration’s Breakthrough Therapy program.
- Financials: As of end 2024, total assets RMB 28.05 million, owner’s equity -RMB 5.49 million, liabilities RMB 33.55 million; 2024 revenue RMB 210,000, net loss RMB 58.35 million. As of October 2025, total assets RMB 15.82 million, equity -RMB 1.08 million, liabilities RMB 16.9 million; no revenue in first 10 months of 2025, net loss RMB 18.08 million.
- R&D Progress and Risks: Main pipelines are still in clinical stage, no marketed products; high uncertainty in clinical progress and regulatory approval; post-launch sales may face multiple uncertainties.
3. Investment and Pricing Analysis
- Valuation Basis: Market method (EV/R&D expense) referencing Hengrui Medicine, Shutaishen, Hualan Bio, etc.; adjusted result for company size, stage, R&D intensity. Final valuation: RMB 1.787 billion.
- Investment Pricing: Fosun Pharma Industrial subscribes RMB 2.936752 million new capital for RMB 217.813912 million; acquires RMB 3.086511 million existing capital for RMB 196.561088 million.
- Closing Conditions: Each investor’s closing is independent; Series B closing is prerequisite for equity transfer. Actual holding ratio depends on respective successful closings.
- Corporate Governance: After transaction, Xingyao Kunze retains 4 directors (Suzhou Fund/Tianjin Fund nominate 3, Anji Kequan 1), 1 supervisor, 1 GM.
4. Impact and Risk Warning
- Investment Purpose: This investment strengthens Fosun Pharma’s liver disease pipeline, enhances core competitiveness. If Xingyao Kunze’s drugs successfully advance and launch, it may break traditional hepatitis B treatment bottlenecks, realize functional cure, and significantly boost company valuation and market attention.
- Risks:
- Products are in clinical stage; high uncertainty and investment risk.
- Post-launch sales depend on demand, competition, channel factors—performance may fluctuate.
- Transaction completion subject to multiple conditions; partial failure does not affect other investors.
5. Approval Process and Historical Related Transactions
- Approval: Independent non-executive directors approved in advance; 7 non-related directors unanimously passed in board; no shareholder meeting required.
- Historical Transactions: Past 12 months, routine related transactions with Suzhou Fund, Tianjin Fund and subsidiaries are minor, mainly raw material sale, service, rent, and property management.
6. Investor Sensitivity & Share Price Impact
- Investor Focus:
- Fosun Pharma’s increased investment in innovative liver drugs—if clinical breakthrough, could trigger significant share price movement.
- Transaction is compliant and not a major asset restructuring.
- High R&D investment and market potential—investors should monitor clinical progress and policy changes.
- High risk—investors must be cautious about R&D uncertainties and market acceptance.
7. Conclusion
This substantial investment by Fosun Pharma into Xingyao Kunze will significantly impact the company’s liver disease drug pipeline. If the core drug successfully enters the market, it could serve as a major share price catalyst. Investors should closely monitor clinical progress and regulatory developments.
Disclaimer
This article is for news reporting and investment reference only and does not constitute investment advice. Investors should fully understand transaction risks and uncertainties and make decisions prudently based on their risk tolerance.
